© 2005-2012 American Society of Clinical Oncology (ASCO). All rights reserved worldwide.
Cancer.Net Specialty Editor: Lung Cancer
Memorial Sloan-Kettering Cancer Center, New York, NY
Lee M. Krug, MD, is an Associate Attending Physician and Director of the Mesothelioma Program at Memorial Sloan-Kettering Cancer Center (MSKCC). Dr. Krug's work focuses on caring for patients with lung cancer and malignant pleural mesothelioma.
Dr. Krug earned his medical degree at Washington University School of Medicine in St. Louis. After finishing his residency at Johns Hopkins Hospital in Baltimore, Maryland, Dr. Krug completed a fellowship at MSKCC.
At MSKCC, Dr. Krug conducts patient-based research by running clinical trials testing novel drugs and treatment strategies for patients with small cell lung cancer and mesothelioma. He led an international Phase III trial of vorinostat for patients with mesothelioma who had previously been treated with chemotherapy. Dr. Krug also has a particular interest in therapies that boost the immune system so that it can recognize and attack specific molecules on the cancer cells. He conducted studies testing ganglioside vaccines in small cell lung cancer and a WT-1 peptide vaccine in mesothelioma, both of which were developed by scientists at MSKCC.
Dr. Krug drafted the first National Comprehensive Cancer Network (NCCN) guidelines for the management of mesothelioma, which have now been approved. He chairs the Scientific Advisory Board for the Mesothelioma Applied Research Foundation.
Disclosure: In the past two year, Dr. Krug served as a consultant/advisor for Poniard Pharmaceuticals, Morphotek, MedImmune, and Genentech; and received research funding from Lilly, Merck, CanBas, and Novartis.
Last Updated: May 24, 2012